AURKA and neuroblastoma: Confirming the importance of this topic, the AURKA inhibitor MLN8237 (also known as alisertib) combined with irinotecan and temozolomide chemotherapy is under clinical assessment for multiple-cancer relapsed NB (NCT01601535) (Table 2) [182].